- Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma
- Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities
- Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
- Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
- Philogen Announces Clinical Trial Collaboration with MSD
- Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
- Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
More ▼
Key statistics
On Friday, Philogen SpA (PHIL:MIL) closed at 17.95, -6.75% below its 52-week high of 19.25, set on Oct 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.95 |
---|---|
High | 18.05 |
Low | 17.85 |
Bid | 17.75 |
Offer | 18.40 |
Previous close | 17.85 |
Average volume | 23.47k |
---|---|
Shares outstanding | 29.24m |
Free float | 240.64k |
P/E (TTM) | -- |
Market cap | 524.91m EUR |
EPS (TTM) | -0.1551 EUR |
Data delayed at least 15 minutes, as of May 03 2024 16:35 BST.
More ▼